Literature DB >> 22036736

Medication adherence and quality of life among Nigerian outpatients with schizophrenia.

Adegoke Oloruntoba Adelufosi1, Timothy Olaolu Adebowale, Olukayode Abayomi, Julianah Temilola Mosanya.   

Abstract

OBJECTIVE: The aim of this study was to examine medication adherence among outpatients with schizophrenia in relation to their subjective quality of life and other sociodemographic, clinical and service related factors.
METHODS: Three hundred and thirteen consecutive outpatient clinic attendees with a Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) diagnosis of schizophrenia confirmed with the Structured Clinical Interview for Diagnosis were recruited for the study. Respondents were interviewed using a questionnaire evaluating sociodemographic, medication, illness and clinic attendance related variables. Medication adherence was assessed using the Morisky medication adherence questionnaire. Participants also completed the World Health Organization Quality of Life Scale-BREF questionnaire as a measure of their subjective quality of life, while severity of illness was measured using the Brief Psychiatric Rating Scale (BPRS).
RESULTS: Overall, 40.3% of the respondents were medication nonadherent. Medication adherent respondents significantly reported their perceived social support as "good" (P=.006), took significantly fewer number of medications (P≤.001), had higher medication use recall scores (P≤.001), had lower total BPRS scores (P=.001) and were "very satisfied" with their outpatient care (P=.002). Independent predictors of medication nonadherence were BPRS score [odds ratio (OR)=1.08, 95% confidence interval (95% CI)=1.03-1.13], outpatient clinic default (OR= 4.97, 95% CI=2.59-9.53) and moderate satisfaction with outpatient care (OR=2.78, 95% CI=1.47-5.24). Medication nonadherence was significantly associated with lower scores on all domains and facets of quality of life.
CONCLUSIONS: Medication nonadherence is common among outpatients with schizophrenia and is associated with poor quality of life. Clinicians' awareness of the risk factors for medication nonadherence early in patients' management may significantly improve treatment outcomes, including patients' quality of life.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22036736     DOI: 10.1016/j.genhosppsych.2011.09.001

Source DB:  PubMed          Journal:  Gen Hosp Psychiatry        ISSN: 0163-8343            Impact factor:   3.238


  15 in total

1.  Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies.

Authors:  John M Kane; Taishiro Kishimoto; Christoph U Correll
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

2.  Relationship between quality of life and social integration among patients with schizophrenia attending a Nigerian tertiary hospital.

Authors:  Temitope Ogundare; Peter O Onifade; 'Deji Ogundapo; Senait Ghebrehiwet; Christina P C Borba; David C Henderson
Journal:  Qual Life Res       Date:  2021-02-01       Impact factor: 4.147

3.  Better quality of life in patients offered financial incentives for taking anti-psychotic medication: Linked to improved adherence or more money?

Authors:  Katherine Moran; Stefan Priebe
Journal:  Qual Life Res       Date:  2016-02-05       Impact factor: 4.147

4.  Psychotropic medicine beliefs, side effects and adherence in schizophrenia: a patient-caregiver dyad perspective.

Authors:  Irene A Kretchy; Bernard Appiah; Kofi Agyabeng; Emmanuel M Kwarteng; Enyonam Ganyaglo; Grace Owusu Aboagye
Journal:  Int J Clin Pharm       Date:  2021-04-09

5.  The knowledge and attitudes of psychiatrists towards antipsychotic long-acting injections in Nigeria.

Authors:  Bawo O James; Joyce O Omoaregba; Kingsley M Okonoda; Edebi U Otefe; Maxine X Patel
Journal:  Ther Adv Psychopharmacol       Date:  2012-10

6.  Demographic and clinical correlates of sexual dysfunction among Nigerian male outpatients on conventional antipsychotic medications.

Authors:  Aina Kikelomo Oyekanmi; Adegoke Oloruntoba Adelufosi; Olukayode Abayomi; Timothy Olaolu Adebowale
Journal:  BMC Res Notes       Date:  2012-06-07

7.  Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia.

Authors:  George Awad; Daisy Ng-Mak; Krithika Rajagopalan; Jay Hsu; Andrei Pikalov; Antony Loebel
Journal:  BMC Psychiatry       Date:  2016-06-01       Impact factor: 3.630

Review 8.  Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness.

Authors:  Dawn I Velligan; Martha Sajatovic; Ainslie Hatch; Pavel Kramata; John P Docherty
Journal:  Patient Prefer Adherence       Date:  2017-03-03       Impact factor: 2.711

9.  Perspectives on reasons for non-adherence to medication in persons with schizophrenia in Ethiopia: a qualitative study of patients, caregivers and health workers.

Authors:  Solomon Teferra; Charlotte Hanlon; Teferra Beyero; Lars Jacobsson; Teshome Shibre
Journal:  BMC Psychiatry       Date:  2013-06-17       Impact factor: 3.630

10.  Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia.

Authors:  George Awad; Mariam Hassan; Antony Loebel; Jay Hsu; Andrei Pikalov; Krithika Rajagopalan
Journal:  BMC Psychiatry       Date:  2014-02-23       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.